Skip to content

Genetic guidance for antidepressants showed an uncertain signal for improved functioning

A pooled disability result favored genetically guided treatment, but lost statistical significance after an alternative statistical adjustment.

By 100HP editorialAbstract-based explanation checked

Based on the published abstract. The full paper may contain additional methods, results and limitations.

The 30-second takeaway

The main pooled analysis suggested less functional disability with pharmacogenetically guided antidepressant treatment than with usual care. However, the result was no longer statistically significant after the Hartung-Knapp adjustment. Together with mixed individual study findings and bias concerns, this means a functional benefit remains uncertain rather than established by the review.

Keep in mind

The evidence base was small, and every included study had at least some risk-of-bias concerns. The abstract does not report follow-up lengths or a separate pooled quality-of-life result.

THE NUMBERS, WITH CONTEXT

What researchers found

Mean difference: -2.85 points (95% CI: -5.44 to -0.26)

Functional disability on the Sheehan Disability Scale/Inventory

Genetically guided treatment versus usual care; timeframe not reported. The main analysis was significant, but the Hartung-Knapp-adjusted result was not.

Eur Neuropsychopharmacol, 2025 · Original source ↓

Functioning was the central reported result

The pooled endpoint concerned disability in daily functioning, rather than depression symptoms alone. Individual studies reported different patterns, including an overall disability result, a social-support component result and a finding of no effect.

Why the adjustment matters

The change in statistical significance shows that the conclusion depends on the analysis used. It does not prove that genetic guidance has no benefit, but it weakens confidence in a firm positive conclusion.

CHECK THE ORIGINAL

The original publication

Efficacy of pharmacogenetic (PGx)-guided antidepressant treatment on functional outcomes and quality of life in adults with anxiety and affective disorders: A systematic review and meta-analysis.

Fares-Otero NE, Budde M, Laatsch J et al.
Eur Neuropsychopharmacol · 2025

PubMed ID
40889463
Record checked

AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.